Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Clinical insights
Key research benefits
Eli Lilly's investigational triple hormone agonist (GLP-1 + GIP + glucagon) — the only compound in this category with large-scale Phase 2/3 human trial data.
- 28.7% average body weight loss at 68 weeks — the largest weight-loss result of any obesity drug tested to date (Phase 3 TRIUMPH-4, Dec. 2025).
- 82–86% relative liver fat reduction at 24 weeks in a dedicated fatty-liver-disease sub-study — the most dramatic liver fat result ever recorded in a drug trial.
- Up to 2.0% HbA1c reduction and 75.8% reduction in knee osteoarthritis pain (WOMAC score) as secondary benefits alongside weight loss.
Research backing
Jastreboff et al., NEJM 2023 (Phase 2, n=338); Sanyal et al., Nature Medicine 2024 (liver fat sub-study); TRIUMPH-4 Phase 3 (2025, n=5,800+ program-wide). Not yet FDA approved — submission expected late 2026/2027.
Research Grade Formula
Retatrutide
Fat Loss & Metabolic Health
Retatrutide · 20mg
$260
Express Shipping $20 — Australia only
- Third-party tested
- Non-GMO
- GMP certified
How to use
Follow research handling and reconstitution guidance for this compound. Always use appropriate lab technique and sterile materials.
Research Dosage ProtocolWhat's inside
This listing supplies Retatrutide research peptide in lyophilized form for metabolic and receptor-pathway laboratory investigations. Handle using sterile reconstitution practices.
Technical overview
- Contents: Retatrutide research peptide
- Form: Freeze-dried powder for lab preparation
- Purity: ≥99% analytical grade
- Verification: RP-HPLC / COA per production lot
- Storage: Cool, dry conditions prior to reconstitution
Reconstitute with bacteriostatic water at room temperature. For laboratory research and educational use only — not for human consumption.
Customer reviews
4.9
Based on 312 reviews
